Piclidenoson — Topline data
Q3 2026
Top-line results are expected in the third quarter of 2026.Source filing
CANF biotech catalysts & pipeline
CAN-FITE BIOPHARMA LTD · Data as of 2026-09-08
Upcoming catalysts
Namodenoson — Interim data
Q4 2026
An interim analysis from the Phase III study is expected to be in approximately Q4 2026.Source filing
Piclidenoson — Interim data
Oct 2026–Mar 2027
Results are expected during Q4 2026/Q1 2027.Source filing
namodenoson — Conference presentation
Oct 23–Oct 27
Clinical results from Can-Fite's Phase 2a study of namodenoson in advanced pancreatic adenocarcinoma have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026.Source filing